Skip to content

Transcranial Stimulation in Motor Stroke Rehabilitation

Safety and Efficacy of Non Invasive Transcranial Brain Stimulation in Motor Stroke Rehabilitation

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02525393
Enrollment
34
Registered
2015-08-17
Start date
2012-03-31
Completion date
2014-07-31
Last updated
2015-08-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stroke

Keywords

Rehabilitation, Non Invasive Brain Stimulation

Brief summary

Patients were randomized in 3 groups: two intervent groups and a control group. The first group received two weeks of daily session of repetitive Transcranial Magnetic Stimulation (rTMS, 10 sessions) and, at least 6 months after, two weeks of daily transcranial Direct Current Stimulation (tDCS, 10 sessions); the second group received 10 daily session of tDCS and, after at least 6 months, 10 sessions of rTMS; the control group received 10 daily session of sham tDCS. Physiatric evaluations (ARAT scale), neuropsychological assessment and ERP (P300) were performed before (1 week) and after (1 week) the end of each treatment. Furthermore, all patients underwent follow-up neuropsychological assessment 6 months after the end of each stimulation period and follow-up physiatric evaluation at 3 and 6 months after the end of each stimulation period.

Interventions

DEVICErTMS

Stroke rehabilitation performed with the aid of a repetitive transcranial magnetic stimulation device.

DEVICESham

Stroke sham stimulation performed with the aid of a transcranial electrical stimulation device.

DEVICEtDCS

Stroke rehabilitation performed with the aid of a transcranial electrical stimulation device.

Sponsors

University of Turin, Italy
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* ischemic or hemorrhagic stroke (\> 6 months from the accident)

Exclusion criteria

* general cognitive impairment (Mini Mental State Examination \< 25), severe functional disability (Barthel Index \< 45), * psychiatric disorders, * degenerative neurological disorders, * epilepsy, * severe medical conditions, * having been implanted a drug infusion system, spinal/brain-stimulator, or endovascular coil

Design outcomes

Primary

MeasureTime frameDescription
Change from the baseline ARAT (measures Grasp, Grip, Pinch, Gross Movement)Baseline; 1 month; 3 months; 6 months; 6 months and 1 week; 7 months; 9 months; 12 monthsAction Research Arm Test (ARAT) measures Grasp, Grip, Pinch, Gross Movement. Baseline is 1 week before first treatment; other time frame: 1 week after first treatment; 3 months after first treatment; 6 months follow-up after first treatment; 1 week before second treatment; 1 week after second treatment; 3 months follow-up after second treatment; 6 months follow-up after second treatment.

Secondary

MeasureTime frameDescription
P300 (latency)Baseline; 1 month; 6 months and 1 week; 7 monthsThe P300 (P3) wave is an event related potential (ERP) component elicited in the process of decision making. Investigators measured the latency of the component 1 week before first treatment; 1 week after first treatment; 1 week before second treatment; 1 week after second treatment.
Cognition (standardized neuropsychological assessment)Baseline; 1 month; 6 months; 6 months and 1 week; 7 months; 12 monthsThe patients were evaluated by means of a standardized neuropsychological assessment consisting of a battery of cognitive tests involving the following domains: verbal short-term memory, visuospatial learning, working memory, verbal learning, attention and frontal executive functions, and general cognitive impairment. The assessment was repeated 1 week before first treatment; 1 week after first treatment; 6 months follow-up after first treatment; 1 week before second treatment; 1 week after second treatment; 6 months follow-up after second treatment.

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026